KAKory L. Alderson

Kory L. Alderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kory L. Alderson has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander L. Rakhmilevich

    Department of Human Oncology, University of Wisconsin-Madison, Madison, USA

    1 shared publication
  • Fariba Navid

    Department of Oncology, St. Jude Children’s Research Hospital, Memphis, USA

    1 shared publication
  • Megan M. Elsenheimer

    Department of Human Oncology, University of Wisconsin-Madison, Madison, USA

    1 shared publication
  • Mitchell Luangrath

    Division of Critical Care, Stead Family Department of Pediatrics, University of Iowa Health Care, Iowa City, IA, USA

    1 shared publication
  • Paul M. Sondel

    Department of Human Oncology, University of Wisconsin-Madison, Madison, USA

    1 shared publication
  • Stephen D. Gillies

    Provenance Biopharmaceuticals Corp., Burlington, USA

    1 shared publication

Latest Publications

  • Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG

    by Kory L. Alderson, Mitchell Luangrath, Megan M. Elsenheimer, Stephen D. Gillies, Fariba Navid, Alexander L. Rakhmilevich, Paul M. Sondel

    Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside GD2, expressed on neuroblastoma and melanoma tumors. Anti-GD2 mAbs (αGD2) can provide clinical benefit in patients with neuroblastoma. An important mechanism of mAb therapy is antibody-dependent cellular cytotoxicity (ADCC). Combinatorial therapeutic strategies can dramatically increase the anti-tumor response elicited by mAbs. We combined a novel αGD2 mAb, hu14.18K322A, with an immunostimulatory regimen of agonist CD40 mAb and class B CpG-ODN 1826 (CpG). Combination immunotherapy was more effective than the single therapeutic components in a syngeneic model of GD2-expressing B16 melanoma with minimal tumor burden. NK cell depletion in B6 mice showed that NK cells were required for the anti-tumor effect; however, anti-tumor responses were also observed in tumor-bearing SCID/beige mice. Thus, NK cell cytotoxicity did not appear to be essential. Peritoneal macrophages from anti-CD40 + CpG-treated mice inhibited tumor cells in vitro in an hu14.18K322A antibody-dependent manner. These data highlight the importance of myeloid cells as potential effectors in immunotherapy regimens utilizing tumor-specific mAb and suggest that further studies are needed to investigate the therapeutic potential of activated myeloid cells and their interaction with NK cells.